Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer

Shimizu,Katsuhiko; Okita,Riki; Saisho,Shinsuke; Maeda,Ai; Nojima,Yuji; Nakata,Masao

doi:10.3892/ol.2017.6340

Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer

Authors:
- Katsuhiko Shimizu
- Riki Okita
- Shinsuke Saisho
- Ai Maeda
- Yuji Nojima
- Masao Nakata
View Affiliations

Affiliations: Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama 701‑0192, Japan
Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6340
Pages: 1615-1620

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The immune microenvironment of primary tumors has been reported to be one of the factors influencing the prognosis of patients with cancer. The tumor‑infiltrating regulatory T cell (Treg) count has previously been revealed to be positively correlated with intratumoral cyclooxygenase‑2 (Cox‑2) expression, and was also associated with poor survival among patients with non‑small cell lung cancer (NSCLC). In addition, the urinary levels of a prostaglandin E2 (PGE2) metabolite (PGE‑M) were used as a biomarker in clinical trials of the Cox‑2 inhibitor celecoxib. In the current prospective study, the association of urinary PGE2 and PGE‑M levels with intratumoral Cox‑2 expression and Treg count was examined in patients with NSCLC. A total of 21 patients with NSCLC who underwent complete resection of the tumor at Kawasaki Medical School Hospital (Kurashiki, Japan) were enrolled. Urine specimens were obtained prior to surgery in order to examine urinary PGE2 and PGE‑M levels. A significant positive association was observed between urinary PGE2 levels and the intratumoral Treg count (P=0.023), but not the intratumoral Cox‑2 expression levels. No significant associations were identified between urinary PGE2 levels and any of the other clinicopathological characteristics examined, including age, sex, smoking history, histology, tumor size, nodal status and disease stage. However, no significant association was observed between urinary PGE‑M levels and the intratumoral Treg count (P=0.069) or Cox‑2 expression. In conclusion, urinary PGE2 levels were positively correlated with intratumoral Treg counts in patients with NSCLC in the current study. This indicates that urinary PGE2 may be an improved biomarker, compared with PGE‑M, for the prediction of intratumoral Treg numbers.

View Figures

View References

1	Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, et al: A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers. J Thorac Oncol. 3:46–52. 2008. View Article : Google Scholar : PubMed/NCBI
2	Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M and Yokoi K: Japanese Joint Committee for Lung Cancer Registration: Japanese lung cancer registry study of 11,663 surgical cases in 2004: Demographic and prognosis changes over decade. J Thorac Oncol. 6:1229–1235. 2011. View Article : Google Scholar : PubMed/NCBI
3	Shimizu K, Okita R and Nakata M: Clinical significance of the tumor microenvironment in non-small cell lung cancer. Ann Transl Med. 1:202013.PubMed/NCBI
4	Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 26:4410–4417. 2008. View Article : Google Scholar : PubMed/NCBI
5	Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM and Busund LT: The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 55:301–312. 2009. View Article : Google Scholar : PubMed/NCBI
6	Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, Ma J, Ma L and You Z: The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer. 10:2202010. View Article : Google Scholar : PubMed/NCBI
7	Takanami I, Takeuchi K and Naruke M: Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 88:2686–2692. 2000. View Article : Google Scholar : PubMed/NCBI
8	Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM and Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 14:5220–5227. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H and Nishimura M: CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 94:1003–1009. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shimizu K, Nakata M, Hirami Y, Yukawa K, Maeda A and Tanemoto K: Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenese-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 5:585–590. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ferretti A, Flanagan VP and Roman JM: Quantitative analysis of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid, the major urinary metabolite of E prostaglandins in man. Anal Biochem. 128:351–358. 1983. View Article : Google Scholar : PubMed/NCBI
12	Wang D and DuBois RN: Urinary PGE-M: A promising cancer biomarker. Cancer Prev Res (Phila). 6:507–510. 2013. View Article : Google Scholar : PubMed/NCBI
13	Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, Wen W, Rothman N, Li HL, Morrow JD and Zheng W: Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol. 24:5010–5016. 2006. View Article : Google Scholar : PubMed/NCBI
14	Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow WH and Abnet CC: Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev. 18:3075–3078. 2009. View Article : Google Scholar : PubMed/NCBI
15	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
16	Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, et al: Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib+ chemotherapy -cancer and leukemia group B trial 30203. J Clin Oncol. 26:848–855. 2008. View Article : Google Scholar : PubMed/NCBI
17	Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, et al: Intratimoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 44:1875–1882. 2008. View Article : Google Scholar : PubMed/NCBI
18	Curiel TJ: Tregs and rethinking cancer immunotherapy. J Clin Invest. 117:1167–1174. 2007. View Article : Google Scholar : PubMed/NCBI
19	Kim JM and Rudensky A: The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev. 212:86–98. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
21	Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating Foxp3+ regulatory T-cells are associated with reccurence in pathologic stage l NSCLC patients. Cancer. 107:2866–2872. 2006. View Article : Google Scholar : PubMed/NCBI
22	Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK and Dubinett SM: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65:5211–5220. 2005. View Article : Google Scholar : PubMed/NCBI
23	Wang D and Dubois RN: Eicosanoids and cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
24	Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, Fornier MN, Hudis CA and Dannenberg AJ: Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer. Cancer Prev Res (Philla). 6:428–436. 2013. View Article : Google Scholar
25	Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH and Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 334:266–275. 2004. View Article : Google Scholar : PubMed/NCBI
26	Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F and Choy H: A phase II study of celecoxib in combination with paclitaxel, carboplatin and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res. 15:2158–2165. 2009. View Article : Google Scholar : PubMed/NCBI
27	Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP and Johnson DH: Targeting cyclooygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res. 11:6634–6640. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M and Nakayama E: Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J Thorac Oncol. 10:74–83. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, et al: Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 129:565–576. 2005. View Article : Google Scholar : PubMed/NCBI
30	Yukawa T, Shimizu K, Maeda A, Yasuda K, Saisho S, Okita R and Nakata M: Cyclooxygenaze-2 genetic variants influence intratumoral infiltration of FoxP3-positive regulatory T cells in non-small cell lung cancer. Oncol Rep. 33:74–80. 2015.PubMed/NCBI